New hope for rare liver disease: phase 3 trial of hepalatide begins
NCT ID NCT07309380
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests a new drug called hepalatide (L47) in 150 adults with chronic hepatitis D, a serious liver infection. Participants are randomly assigned to receive either hepalatide or a placebo daily for 48 weeks, followed by an optional open-label phase. The goal is to see if the drug can lower virus levels and improve liver health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Hospital of Jilin University
Changchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.